Menu

1 / 34

Why Is CG Oncology Stock Soaring Today? - CG Oncology (NASDAQ:CGON)

Top Stories Feed·Vandana Singh·about 3 hours ago
#R90LEsRc
#benzinga#oncology#stock#risk#high
Reading 0:00
15s threshold

November 16, 2026 1:09 PM 2 min read

CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds

by Vandana Singh Benzinga Staff Writer

Follow

CGONCG Oncology Inc

$86.6616.5%

Stock Score Locked: Want to See it?

Benzinga Edge Rankings give you vital metrics on any stock – anytime.

Reveal Full Score Edge Rankings

Momentum93.08

GrowthN/A

QualityN/A

ValueN/A

Price Trend

ShortMediumLongOverview CG Oncology Inc. (NASDAQ:CGON) on Monday announced positive topline results from its Phase 3 PIVOT-006 trial, which Arthur Kuan, chairman, president, and CEO of CG Oncology, called a defining milestone for the company.

Kuan stated that the data position cretostimogene grenadenorepvec as the first and only therapeutic candidate to show a significant recurrence benefit in a pivotal Phase 3 study for intermediate-risk and high-grade Ta NMIBC, prompting the company to advance two BLA filings in 2027.

PIVOT-006 Trial Delivers 68% Recurrence Risk Reduction

The registrational PIVOT-006 study…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.